Related Experiment Video

Updated: May 11, 2026

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice
07:37

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice

Published on: June 6, 2025

Juvenile idiopathic arthritis in the new world of biologics

Genevieve Tyra Ostring1, Davinder Singh-Grewal

  • 1Department of Paediatrics, Waitakere Hospital, Auckland, New Zealand; The School of Medicine, Paediatrics, The University of Auckland, Auckland, New Zealand.

Journal of Paediatrics and Child Health
|May 8, 2013
PubMed

Insights

Juvenile idiopathic arthritis (JIA) causes pain and disability. Early diagnosis and new biologic agents offer improved outcomes, but long-term effects require further study.

Area of Science:

  • Pediatric Rheumatology
  • Immunology

Background:

  • Juvenile idiopathic arthritis (JIA) presents significant pain and disability in pediatric and adult populations.
  • While treatment advances have improved long-term outcomes, early and aggressive management is crucial for further enhancement.

Purpose of the Study:

  • To review current understanding and management of Juvenile Idiopathic Arthritis.
  • To highlight the role of early diagnosis, emerging therapies, and ongoing research needs.

Main Methods:

  • Literature review of JIA diagnosis, treatment modalities, and management strategies.
  • Discussion of current therapeutic options including intra-articular steroids, methotrexate, and biologic agents.
  • Emphasis on the diagnostic challenges and the need for potential biomarkers.

Main Results:

  • JIA is a clinical diagnosis of exclusion, necessitating further research for specific biomarkers.
  • Biologic agents offer novel treatment avenues but carry unknown long-term immunomodulatory risks.
  • Screening for uveitis and multidisciplinary care are essential components of JIA management.

Conclusions:

  • Early and aggressive management of JIA is key to improving patient outcomes.
  • Continued research into biological markers and long-term effects of biologic therapies is warranted.
  • Comprehensive, multidisciplinary care, including uveitis screening, is vital for managing JIA.

Keywords:
biological drugsintra-articular steroid injectionsjuvenile idiopathic arthritismethotrexatemultidisciplinary teamuveitis

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Autoimmune Disorders01:29

Autoimmune Disorders

Autoimmune diseases are a group of disorders in which the body's immune system mistakenly attacks its own cells, tissues, and organs. This results from an overactive immune response against substances and tissues normally present in the body. Let's delve into the concept and mechanism of autoimmune diseases from an immune system point of view, explore different causes and examples of such diseases, and discuss potential solutions.
Concept and Mechanism of Autoimmune Diseases
The immune system...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Drug Products: Biologics, Biosimilars and Interchangeables01:28

Drug Products: Biologics, Biosimilars and Interchangeables

Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...